Diwakar Davar

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Diwakar Davar

Nov 10, 2024, 14:28 | Insight

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101)

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101),…

Aug 6, 2024, 10:23 | Blog

Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors

Journal for ImmunoTherapy of Cancer made the following post on X: "New JITC article: Phase I…

Jun 27, 2024, 15:26 | Opinion

Diwakar Davar and Jason Luke discuss high-risk melanoma from the NADINA trial

The American Society of Clinical Oncology (ASCO) shared on X: "Diwakar Davar and Jason Luke…

May 29, 2024, 11:10 | Blog

The future of immunotherapy in melanoma and beyond on the ASCO Daily News Podcast

ASCO made the following post on X: "Diwakar Davar & Jason Luke of UPMC Hillman Cancer…

May 29, 2024, 10:00 | Blog

Jason Luke: Discussing ASCO24 abstracts with Diwakar Davar

Jason Luke, Associate Professor at the University of Pittsburgh, shared a post on X: "Appreciated…

All: 5 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023